The Hiatal Herniator® treatment (HHT) is a highly-selective treatment that targets both the prostate and the bladder.
This treatment is especially beneficial for those with recurrent bladder or urinary incontinence and can help with both chronic and chronic bladder disease.
The Hiatal HHT was initially developed to treat prostate cancer and prostate cancer related incontinentness, but has since been shown to be beneficial for both men and women with chronic bladder and urinary incretinitis.
As part of the trial, the Hiatal treatment is currently being studied in people over the age of 50 who have chronic urinary incorbidity.
The treatment consists of two components: an injection of a hormone-based gel, which is injected into the prostate gland, and a small tablet containing a blend of HHT and a drug called a biotin peptide.
The hormone-free gel has a longer duration and lower side effects than the HHT.
The trial has already started and is expected to be completed within two to three months, according to a press release from the US National Institutes of Health.
In the trial phase, the hormone-containing gel is injected twice daily and then the tablet is absorbed by the body.
After the tablets are absorbed, they are then administered once daily.
This is a trial with more than 10,000 participants, but the team expects to see many more participants in the near future.
The trial is part of a larger NIH-funded initiative called TRILL (Trials of Long-Term Improvement), which is designed to find treatments for incontaminations that last longer than one year.
The research team has also been working with a pharmaceutical company to conduct a Phase 3 clinical trial.
The company is planning to use the Hiatum HHT to treat patients with recurrent urinary incisors and urinary retention disorder, and they are also planning to test the Hiatapla HHT for a similar type of incontamination.